FindTrial
Sign In

Action of Punarnava Ghanavati on kidney.

A Clinical Evaluation of Punarnava Ghanavati in Chronic Kidney Disease W. S. R. To Electolytes.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026751
Enrollment
90
Registered
2020-07-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E878- Other disorders of electrolyte andfluid balance, not elsewhere classified

Interventions

Intervention1: Punarnava Ghanavati: Punarnava Ghanavati 500mg twice a day orally for 3 months with water along with conventional treatment to be given in the patient of CKD. Control Intervention1: NIL

Sponsors

Amit Gujrathi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Confirmed cases of CKD with raised microalbuminuria. Patients of CKD having GFR less than 90ml/min; serum creatinine not more than 15mg%. proteinuria not more than 300 mg/day. CKD patient with HTN, DM, thyroid illness are to be included.

Exclusion criteria

Exclusion criteria: Patients excluded from inclusion criteria are excluded.

Design outcomes

Primary

MeasureTime frame
Punarnava Ghanavati can be used as renal protective in the patients of CKDTimepoint: 12 weeks—

Secondary

MeasureTime frame
Punarnava Ghanavati can result in micro-albuminuria and overt-proteinuria.Timepoint: 3months—

Countries

India

Contacts

Public ContactDr Amit Gujrathi

Parul Institute of Ayurveda

dr.kku1958@yahoo.in9925765075

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026